RESUMEN
BACKGROUND: The benefits of supplemental vitamin D3, marine omega-3 fatty acids, and a simple home exercise program (SHEP) on frailty prevention in generally healthy community-dwelling older adults are unclear. OBJECTIVE: To test the effect of vitamin D3, omega-3s, and a SHEP, alone or in combination on incident pre-frailty and frailty in robust older adults over a follow-up of 36 months. METHODS: DO-HEALTH is a multi-center, double-blind, placebo-controlled, 2x2x2 factorial randomized clinical trial among generally healthy European adults aged 70 years or older, who had no major health events in the 5 years prior to enrollment, sufficient mobility and intact cognitive function. As a secondary outcome of the DO-HEALTH trial, among the subset of participants who were robust at baseline, we tested the individual and combined benefits of supplemental 2,000 IU/day of vitamin D3, 1 g/day of marine omega-3s, and a SHEP on the odds of being pre-frail and frail over 3 years of follow-up. RESULTS: At baseline, 1,137 out of 2,157 participants were robust (mean age 74.3 years, 56.5% women, mean gait speed 1.18 m/s). Over a median follow-up time of 2.9 years, 696 (61.2%) became pre-frail and 29 (2.6%) frail. Odds ratios for becoming pre-frail were not significantly lower for vitamin D3, or omega 3-s, or SHEP, individually, compared to control (placebo for the supplements and control exercise). However, the three treatments combined showed significantly decreased odds (OR 0.61 [95% CI 0.38-0.98; p=0.04) of becoming pre-frail compared to control. None of the individual treatments or their combination significantly reduced the odds of becoming frail. CONCLUSION: Robust, generally healthy and active older adults without major comorbidities, may benefit from a combination of high-dose, supplemental vitamin D3, marine omega-3s, and SHEP with regard to the risk of becoming pre-frail over 3 years.
Asunto(s)
Ácidos Grasos Omega-3 , Fragilidad , Humanos , Femenino , Anciano , Masculino , Vitamina D , Fragilidad/prevención & control , Fragilidad/tratamiento farmacológico , Vitaminas/uso terapéutico , Ácidos Grasos Omega-3/uso terapéutico , Colecalciferol/uso terapéutico , Suplementos Dietéticos , Terapia por EjercicioRESUMEN
Life expectancy of people living with HIV (PLWH) is reaching similar length as in the general population. Accordingly, age-related comorbidities, including osteoporosis, are increasing. Fracture risk is higher and increases approximately 10 years earlier in PLWH. Classical risk factors of bone fragility are highly prevalent in PLWH but factors specific for HIV infection itself and the type of antiretroviral therapy (ART) (triple combination antiretroviral therapy) regimen (especially tenofovir and protease inhibitors) also contribute to bone loss. The majority of bone loss occurs during virus activity and at initiation of ART (immune reconstitution) and is associated with an increase of bone resorption (upregulation RANKL). Recent data indicate that calcium and vitamin D supplements as ART initiation lower BMD loss. The reduction of tenofovir plasma concentrations with tenofovir alafenamide attenuates BMD loss but it remains unknown whether it will contribute to reduce fracture risk. Hence, special considerations for the management of bone fragility in PLWH are warranted. Based on the current state of epidemiology and pathophysiology of osteoporosis in PLWH, we provide the consensus of the Swiss Association against Osteoporosis on best practice for diagnosis, prevention, and management of osteoporosis in this population. Periodic assessment of fracture risk is indicated in all HIV patients and general preventive measures should be implemented. All postmenopausal women, men above 50 years of age, and patients with other clinical risk for fragility fractures qualify for BMD measurement. An algorithm clarifies when treatment with bisphosphonates and review of ART regimen in favour of more bone-friendly options are indicated.
Asunto(s)
Infecciones por VIH/complicaciones , Osteoporosis/etiología , Fármacos Anti-VIH/efectos adversos , Densidad Ósea/efectos de los fármacos , Conservadores de la Densidad Ósea/uso terapéutico , Infecciones por VIH/epidemiología , Humanos , Osteoporosis/diagnóstico , Osteoporosis/epidemiología , Osteoporosis/terapia , Fracturas Osteoporóticas/epidemiología , Fracturas Osteoporóticas/fisiopatología , Fracturas Osteoporóticas/prevención & control , Medición de Riesgo/métodos , Factores de Riesgo , Suiza/epidemiologíaRESUMEN
UNLABELLED: In this double-blind RCT, 4-month treatment with calcifediol compared with vitamin D3 improved gait speed by 18% among young postmenopausal women. Consistently, change in 25(OH)D blood levels over time were significantly correlated with improvement in gait speed in these women. No effect could be demonstrated for trunk sway. INTRODUCTION: The aim of this study is to test the effect of calcifediol compared with vitamin D3 on gait speed and trunk sway. METHODS: Twenty healthy postmenopausal women with an average 25(OH)D level of 13.2 ng/ml (SD = ±3.9) and a mean age of 61.5 years (SD = ±7.2) were randomized to either 20 µg of calcifediol or 20 µg (800 IU) of vitamin D3 per day in a double-blind manner. At baseline and at 4 months of follow-up, the same physiotherapist blinded to treatment allocation tested 8-m gait speed and a body sway test battery (Sway star pitch and roll angle plus velocity while walking 8 m, and standing on both legs on a hard and soft surface). All analyses adjusted for baseline measurement, age, and body mass index. RESULTS: Mean 25(OH)D levels increased to 69.3 ng/ml (SD = ±9.5) in the calcifediol group and to 30.5 ng/ml (SD = ±5.0) in the vitamin D3 group (p < 0.0001). Women receiving calcifediol compared with vitamin D3 had an 18% greater improvement in gait speed at 4-month follow-up (p = 0.046) adjusting for baseline gait speed, age, and body mass index. Also, change in gait speed was significantly correlated with change in serum 25(OH)D concentrations (r = 0.5; p = 0.04). Across three tests of trunk sway, there were no consistent differences between groups and no significant correlation between change in 25(OH)D serum concentrations and change in trunk sway. CONCLUSIONS: Calcifediol improved gait speed in early postmenopausal women compared with vitamin D3 and change in 25(OH)D level was moderately correlated with improvement in gait speed. A benefit on trunk sway could not be demonstrated.
Asunto(s)
Calcifediol/farmacología , Colecalciferol/farmacología , Suplementos Dietéticos , Marcha/efectos de los fármacos , Posmenopausia/fisiología , Anciano , Calcifediol/sangre , Calcitriol/sangre , Método Doble Ciego , Femenino , Marcha/fisiología , Humanos , Persona de Mediana Edad , Hormona Paratiroidea/sangre , Posmenopausia/sangre , Propiocepción/efectos de los fármacos , Torso/fisiología , Vitamina D/análogos & derivados , Vitamina D/sangreRESUMEN
BACKGROUND: In order to introduce elderly people to be physically active, it is necessary to evaluate which types of exercise show a high adherence. Therefore, the objective of this systematic literature review was to determine adherence rates in intervention programs to promote physical activity in older adults. METHODS: Forty-six studies investigating the effects of aerobic, resistance, power, balance, Tai Chi training, and multimodal training were included following a systematic literature search. Adherence rates were evaluated using multiple linear regression analysis. RESULTS: No significant correlations were observed between adherence rates and exercise programs. However, there was a significant association between adherence rate and training frequency (-2,9%; p=0,042), training duration (-0,2%; p=0,016) and number of participants (-0,1%; p=0,008). CONCLUSION: To ensure a high adherence to training programs with older people, it seems that to a lesser extent the contents of training, but rather the training modalities (i.e., training frequency, intervention duration) and the number of participants appear to be of importance.
Asunto(s)
Ejercicio Físico , Promoción de la Salud , Actividad Motora , Cooperación del Paciente , Anciano , Anciano de 80 o más Años , Ensayos Clínicos como Asunto , Femenino , Humanos , Masculino , Modalidades de Fisioterapia , Resultado del TratamientoRESUMEN
Examining gait characteristics in older adults enhances our understanding of movement control in this population and helps to better target preventive interventions. Walking is a highly automated, regular motor behavior that is mostly controlled by subcortical locomotor brain regions. With increasing age, walking requires higher levels of attention and thus more cortical involvement in motor control. This can affect gait regularity by increasing stride-to-stride variability that is characteristically high among fallers. A growing number of clinical gait analysis systems is now available to determine gait variability and thus the falling risk in older adults. Interventions targeting high gait variability in older adults need to consider basic principles of motor learning. Previously common and automatic gait patterns have to be relearned and again brought up to a highly automated level of motor control. Regular walking exercise, and particularly T'ai Chi with its emphasis on sequenced, slow, and highly controlled movements, might be helpful in this relearning process. Further research is needed to explore other interventions that could favorably affect stride-to-stride variability of older adults.